We are a commercial-stage biopharmaceutical company committed to the research, development, manufacturing, and commercialization of internally developed and in-licensed innovative drugs for organ fibrosis for two decades.

Front runner in the treatment of organ fibrosis
We have long been focusing on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened our therapeutic field and R&D efforts to other areas of organ fibrosis. The flagship product ETUARY® (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. Filling IPF treatment vaccum in China, ETUARY® has developed rapidly and achieved a dominant market share in China in 2020. And ETUARY® has been included in the national reimbursement drug list since 2017. While continuously advancing the research and development of our pipeline products, we are one of a few of biopharmaceutical companies focusing on organ fibrosis drugs in China with manufacturing and commercialization capabilities and track record.

Committed to bringing hope through innovation to patients with organ fibrosis
We will enrich and promote our product pipeline by leveraging on our successful and complete experience accumulated from in-house development to commercialization of ETUARY®. And we will also focus on organ fibrosis by researching and developing the treatment of pulmonary fibrosis, liver fibrosis and renal fibrosis.